Merck Serono and F-star Form Next-Generation Antibody Development Pact
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)
Published: 19 Sep-2011
DOI: 10.3833/pdr.v2011.i9.1543 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
F-star has signed a research, licence and commercialisation agreement with Merck Serono, potentially worth up to €492 M (US$692 M) for the discovery of novel monospecific Fc-based targeted biologics (Fcab™) and bispecific IgG-based targeted biologics (mAb² ™) against up to three inflammatory disease targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS